Literature DB >> 8992992

The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor.

N I Obiri1, P Leland, T Murata, W Debinski, R K Puri.   

Abstract

We have reported on the expression and characteristics of IL-13R and have demonstrated that IL-13 competes for IL-4 binding while IL-4 did not compete for the IL-13 binding on some cell types. Based on these observations, and the size of IL-13 and IL-4 cross-linked proteins, we concluded that the receptor for IL-13 is complex and shares a subunit with the receptor for IL-4. To explore the complexity of the IL-13R, a wide variety of cell types was examined for IL-13 and IL-4 binding. We report in this work that IL-4 does not always bind well to cells that bind IL-13, but the reverse is also true. We also found that IL-4 can compete more effectively for IL-13 binding than IL-13 itself. Cross-linking studies support these observations and demonstrate that 125I-labeled IL-13 bound exclusively to a single 65- to 70-kDa protein in MA-RCC and U251 cells, while in TF-1 cells it cross-linked to two membrane proteins of 65 to 70 kDa and 140 kDa. Furthermore, by using a chimeric protein composed of IL-13 and Pseudomonas exotoxin A, we observed that IL-4 neutralized the cytotoxicity of the IL-13 toxin on COS-7 cells by blocking a common form of the two cytokine receptors. We propose that the 65- to 70-kDa form of the IL-13R is the predominant common component shared between IL-13 and IL-4R. However, the primary IL-4 binding (p140) protein also participates in the formation of the IL-13R complex in some cell types. In addition, the gamma(c) or another interactive subunit may influence IL-13 binding to its receptor complex. Thus, we propose that there are at least four forms of IL-13R.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8992992

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  32 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

3.  Interaction affinity between cytokine receptor components on the cell surface.

Authors:  A Whitty; N Raskin; D L Olson; C W Borysenko; C M Ambrose; C D Benjamin; L C Burkly
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 4.  A primer on cytokines: sources, receptors, effects, and inducers.

Authors:  J H Curfs; J F Meis; J A Hoogkamp-Korstanje
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 5.  Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

Authors:  Marianela Candolfi; Kurt M Kroeger; Weidong Xiong; Chunyan Liu; Mariana Puntel; Kader Yagiz; Akm Ghulam Muhammad; Yohei Mineharu; David Foulad; Mia Wibowo; Hikmat Assi; Gregory J Baker; Pedro R Lowenstein; Maria G Castro
Journal:  Anticancer Agents Med Chem       Date:  2011-10       Impact factor: 2.505

6.  Molecular cloning of the rat IL-13 alpha 2 receptor cDNA and its expression in rat tissues.

Authors:  An-Hua Wu; Walter C Low
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

7.  Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

Authors:  Debasmita Mandal; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

8.  Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  C Jakubzick; E S Choi; S L Kunkel; H Evanoff; F J Martinez; R K Puri; K R Flaherty; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.

Authors:  Edwin W Lai; Bharat H Joshi; Lucia Martiniova; Ritika Dogra; Toshio Fujisawa; Pamela Leland; Ronald R de Krijger; Irina A Lubensky; Abdel G Elkahloun; John C Morris; Raj K Puri; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

10.  Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.

Authors:  Rogério S Rosada; Ana P Moreira; Fabiani G Frantz; Raj K Puri; Aquilur Rahman; Theodore J Standiford; Carlos R Zárate-Bladés; Célio L Silva; Cory M Hogaboam
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.